Latest Industry Insights

Trisha Rice, VP & GM Materials Science Business at Thermo Fisher Scientific, shares her experiences as a woman in science, and provides tips on how to be your most "authentic self" in the field.

Genomic approaches, such as whole exome sequencing, can provide key information to help experts detect rare diseases, but their use still presents challenges. We recently spoke with Gioia Althoff, Vice President, Genomics, at SOPHiA GENETICS, to learn more about the role that whole exome sequencing can play in the fight against rare diseases and how their new solution can help.

Recently, we interviewed George Karlin-Neumann, Clinical Director, Digital Biology Group at Bio-Rad Laboratories to learn more about ddPCR and its applications.

Agilent are working to increase the utility of NGS in the diagnostics field and in personalized medicine. We recently spoke with Ronda Allen, Head of R&D at Agilent, to learn more about two of Agilent's newest products in this space, the Cancer All-in-one (AIO) panels, and the Magnis NGS Library Prep System.

We spoke to Daniel Rooke, Head of Operations and Legal at Start Codon, to learn more about the company and how they can help early stage healthcare and life science businesses in the UK to get off the ground.

Technology Networks recently spoke with Rosengarten and Raymond Mercier, VP and GM, Molecular Biology, Thermo Fisher Scientific, to learn more about how the co-marketing agreement between Thermo Fisher Scientific and Genialis will help ease the burden of the "informatics bottleneck" for research scientists.

In this article, Gary Kruppa, VP of Proteomics at Bruker Daltonics, explores how proteomic methods can help achieve the ultimate goal of preventing and improving the treatment of disease.

Surgery, when used as a cancer treatment, is a procedure in which a surgeon identifies and removes the cancerous tissue from a patient’s body. We recently spoke with Christopher Barys, CEO at On Target Laboratories to learn more about the novel cancer imaging agents they are currently developing, designed to help surgeons identify and resect cancerous lesions.

A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.

We recently spoke with Jed Coleman, co-founder of Curve.life, an online service aiming to provide cancer patients with evidence-based information about how they can empower themselves after diagnosis.